News

The decision was made in light of an upward trend in spontaneous reports of adverse reactions, including syncope (fainting), which are temporally correlated with the liquid Leukine 500mcg

Previously, Mr. Bender was chief technology officer and interim CEO of Emisphere Technologies, a biopharmaceutical company. The company expects to add Mr. Bender to its board of directors

Tri-anim will distribute the full line of Parker’s revolutionary Flex-Tip Tracheal Tubes, which are designed to facilitate fast, easy intubation, and to prevent damage to the patient’s airway

The patent will expire in January 2025. Auxilium plans to list the patent promptly in approved drug products with therapeutic equivalence evaluations (commonly known as the Orange Book),

On-X will market this system to cardiothoracic surgeons nationwide for closed-chest ablation procedures. The system can also be used in open chest, concomitant cases. Robert Cheney, CEO of

John O’Mullane, group vice-president, R&D, Schering-Plough Consumer Health Care, said: “Schering-Plough is pleased that the FDA has approved the change to the Claritin label to help us to

Under the terms of the three-to-five year agreements, research will begin in early 2008. The assay development research relies on NUI Galway nucleic acid detection technology for both

A grant of orphan drug status provides seven years of market exclusivity for the orphan indication after approval by the FDA, as well study design assistance, and eligibility

The dosing regimen for Nebido (testosterone undecanoate) submitted in the original NDA was 1000mg given every 12 weeks. This recently completed additional Phase III trial has studied a